Stock SGMT SAGIMET BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq
Other stock markets
 03:30:00 05/06/2024 am IST 		5-day change 1st Jan Change
4.64 USD -7.57% Intraday chart for Sagimet Biosciences Inc. -12.95% -14.39%
06/06 Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial MT
06/06 Exchange-Traded Funds Edge Up, Equity Futures Mixed Pre-Bell Thursday as Investors Await Fresh Data MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial
MT
Exchange-Traded Funds Edge Up, Equity Futures Mixed Pre-Bell Thursday as Investors Await Fresh Data
MT
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
GL
Sagimet Biosciences Inc. Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
CI
Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating
MT
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
GL
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
AQ
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GL
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
AQ
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
GL
Sagimet Biosciences Names Thierry Chauche CFO
MT
Sagimet Biosciences Inc. Announces Executive Changes
CI
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
GL
Sagimet Biosciences Inc. Announces Appointment of Thierry Chauche as Chief Financial Officer
CI
HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target
MT
Certain Warrants of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Certain Options of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Certain Series A Common Stock of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMT Stock
  4. News Sagimet Biosciences Inc.